Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Case studies for practical food effect assessments across BCS/BDDCS class compounds using in silico, in vitro, and preclinical in vivo data.

Heimbach T, Xia B, Lin TH, He H.

AAPS J. 2013 Jan;15(1):143-58. doi: 10.1208/s12248-012-9419-5. Epub 2012 Nov 10.

2.

pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery.

Varma MV, Gardner I, Steyn SJ, Nkansah P, Rotter CJ, Whitney-Pickett C, Zhang H, Di L, Cram M, Fenner KS, El-Kattan AF.

Mol Pharm. 2012 May 7;9(5):1199-212. doi: 10.1021/mp2004912. Epub 2012 Apr 26.

PMID:
22489626
3.

Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine.

Patel N, Polak S, Jamei M, Rostami-Hodjegan A, Turner DB.

Eur J Pharm Sci. 2014 Jun 16;57:240-9. doi: 10.1016/j.ejps.2013.09.006. Epub 2013 Sep 21.

PMID:
24060671
4.

In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.

Sjögren E, Westergren J, Grant I, Hanisch G, Lindfors L, Lennernäs H, Abrahamsson B, Tannergren C.

Eur J Pharm Sci. 2013 Jul 16;49(4):679-98. doi: 10.1016/j.ejps.2013.05.019. Epub 2013 May 29.

PMID:
23727464
5.

Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds.

Zhang T, Heimbach T, Lin W, Zhang J, He H.

J Pharm Sci. 2015 Sep;104(9):2795-806. doi: 10.1002/jps.24373. Epub 2015 Feb 17.

PMID:
25690565
6.

Provisional classification and in silico study of biopharmaceutical system based on caco-2 cell permeability and dose number.

Pham-The H, Garrigues T, Bermejo M, González-Álvarez I, Monteagudo MC, Cabrera-Pérez MÁ.

Mol Pharm. 2013 Jun 3;10(6):2445-61. doi: 10.1021/mp4000585. Epub 2013 May 15.

PMID:
23675957
8.

Is the full potential of the biopharmaceutics classification system reached?

Bergström CA, Andersson SB, Fagerberg JH, Ragnarsson G, Lindahl A.

Eur J Pharm Sci. 2014 Jun 16;57:224-31. doi: 10.1016/j.ejps.2013.09.010. Epub 2013 Sep 25.

PMID:
24075971
9.

Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir.

Shono Y, Jantratid E, Dressman JB.

Eur J Pharm Biopharm. 2011 Oct;79(2):349-56. doi: 10.1016/j.ejpb.2011.04.005. Epub 2011 Apr 18.

PMID:
21527341
10.

Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling.

Shono Y, Jantratid E, Janssen N, Kesisoglou F, Mao Y, Vertzoni M, Reppas C, Dressman JB.

Eur J Pharm Biopharm. 2009 Sep;73(1):107-14. doi: 10.1016/j.ejpb.2009.05.009. Epub 2009 May 22.

PMID:
19465123
11.

Utility of physiologically based modeling and preclinical in vitro/in vivo data to mitigate positive food effect in a BCS class 2 compound.

Xia B, Heimbach T, Lin TH, Li S, Zhang H, Sheng J, He H.

AAPS PharmSciTech. 2013 Sep;14(3):1255-66. doi: 10.1208/s12249-013-0018-2. Epub 2013 Aug 17.

12.

Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model.

Wagner C, Jantratid E, Kesisoglou F, Vertzoni M, Reppas C, B Dressman J.

Eur J Pharm Biopharm. 2012 Sep;82(1):127-38. doi: 10.1016/j.ejpb.2012.05.008. Epub 2012 May 28.

PMID:
22652546
13.
14.

BDDCS Predictions, Self-Correcting Aspects of BDDCS Assignments, BDDCS Assignment Corrections, and Classification for more than 175 Additional Drugs.

Hosey CM, Chan R, Benet LZ.

AAPS J. 2016 Jan;18(1):251-60. doi: 10.1208/s12248-015-9845-2. Epub 2015 Nov 20. Review.

15.

BDDCS class prediction for new molecular entities.

Broccatelli F, Cruciani G, Benet LZ, Oprea TI.

Mol Pharm. 2012 Mar 5;9(3):570-80. doi: 10.1021/mp2004302. Epub 2012 Feb 7.

16.
17.

Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling.

Jones HM, Parrott N, Ohlenbusch G, Lavé T.

Clin Pharmacokinet. 2006;45(12):1213-26.

PMID:
17112297
18.

Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test.

Takano R, Sugano K, Higashida A, Hayashi Y, Machida M, Aso Y, Yamashita S.

Pharm Res. 2006 Jun;23(6):1144-56. Epub 2006 May 25.

PMID:
16715363
19.

A modified physiological BCS for prediction of intestinal absorption in drug discovery.

Zaki NM, Artursson P, Bergström CA.

Mol Pharm. 2010 Oct 4;7(5):1478-87. doi: 10.1021/mp100124f. Epub 2010 Sep 1.

PMID:
20734997
20.

A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: a cross-sectional survey with 500 bioequivalence studies.

Cristofoletti R, Chiann C, Dressman JB, Storpirtis S.

J Pharm Sci. 2013 Sep;102(9):3136-44. doi: 10.1002/jps.23515. Epub 2013 Apr 11.

PMID:
23580377

Supplemental Content

Support Center